🇧🇪 UCB.BR — UCB SA

Salud Compra
← Volver

Precio actual

290,90 EUR

Máx. histórico

290,90

0 días

Caída desde máximo

En máximo

Rango 52 semanas

197,45 – 292,20

Variación hoy

+0,24%

Cierre anterior

290,20

Rango de hoy

279,10 – 291,20

Volumen hoy

260.813

Peor caída histórica

-66,30%

15/12/2006 → 27/10/2008

Recuperado en 1466 días

Volatilidad anualizada ⓘ

28,70%

Información
Nombre completo
UCB SA
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
9.000
PER ⓘ
25,70 (puede no estar actualizado)
Dividend yield
0,50% (puede no estar actualizado)
Precio objetivo analistas
291,58 EUR (puede no estar actualizado)
Primera cotización
04/01/2000
Precio actualizado
hace 1 día
Sobre la empresa

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Dividendos repartidos Total últimos 12 meses: 1,4500 EUR · Yield: 0,50%
Fecha de pago Importe por participación
04/05/2026 1,4500 EUR
25/04/2025 1,3900 EUR
26/04/2024 1,3600 EUR
28/04/2023 1,3300 EUR
29/04/2022 1,3000 EUR
30/04/2021 1,2700 EUR
04/05/2020 1,2400 EUR
26/04/2019 1,2100 EUR
27/04/2018 1,1800 EUR
28/04/2017 1,1500 EUR
29/04/2016 1,1000 EUR
04/05/2015 1,0600 EUR
29/04/2014 1,0400 EUR
02/05/2013 1,0200 EUR
27/04/2012 1,0000 EUR
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
02/01/2017 60,74 61,50 60,72 61,27 +0,59% 1,28% 102.177
30/12/2016 61,54 61,74 60,91 60,91 -1,34% 1,35% 137.443
29/12/2016 60,90 61,74 60,82 61,74 +0,96% 1,51% 107.036
28/12/2016 60,90 61,24 60,75 61,15 +0,44% 0,80% 133.423
27/12/2016 61,15 61,55 60,75 60,88 -0,20% 1,31% 140.869
23/12/2016 60,72 61,28 60,65 61,00 +0,31% 1,04% 174.941
22/12/2016 60,21 60,81 60,12 60,81 +1,10% 1,15% 232.375
21/12/2016 59,77 60,15 59,32 60,15 +0,28% 1,39% 260.395
20/12/2016 58,24 60,44 58,24 59,98 +2,23% 3,78% 401.765
19/12/2016 58,69 58,70 57,51 58,67 +0,24% 2,03% 310.069
16/12/2016 57,04 58,85 57,04 58,53 +2,54% 3,17% 691.085
15/12/2016 57,10 57,24 56,50 57,08 +0,40% 1,30% 390.933
14/12/2016 57,33 57,33 56,43 56,85 -1,13% 1,57% 390.251
13/12/2016 55,59 57,94 55,16 57,50 +3,16% 5,00% 548.465
12/12/2016 56,59 57,24 55,73 55,74 -1,35% 2,67% 537.339
09/12/2016 59,00 59,25 54,84 56,50 -3,94% 7,47% 1.278.729
08/12/2016 59,16 59,37 58,64 58,82 -0,41% 1,23% 372.081
07/12/2016 59,53 59,73 58,70 59,06 +0,00% 1,73% 341.080
06/12/2016 58,85 59,16 58,65 59,06 +0,44% 0,87% 245.170
05/12/2016 59,33 60,17 58,62 58,80 -1,24% 2,61% 339.334
02/12/2016 59,40 59,84 58,87 59,54 -0,10% 1,63% 277.527
01/12/2016 60,36 60,78 59,36 59,60 -1,81% 2,35% 431.015
30/11/2016 61,24 61,65 60,62 60,70 -1,30% 1,68% 421.975
29/11/2016 61,41 61,68 60,95 61,50 -0,74% 1,19% 263.688
28/11/2016 62,18 62,39 61,64 61,96 -0,78% 1,21% 190.890
25/11/2016 61,80 62,50 61,80 62,45 +1,45% 1,13% 273.366
24/11/2016 61,88 62,00 61,45 61,56 +0,10% 0,89% 274.991
23/11/2016 61,25 61,78 61,13 61,50 +0,52% 1,06% 319.279
22/11/2016 62,04 62,38 61,15 61,18 -0,92% 1,98% 269.006
21/11/2016 62,00 62,22 61,53 61,75 -0,19% 1,11% 230.149